Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1253689/000155837020001723/glyc-20191231x10k.htm
SEC Filings
GLYC Annual Reports
GLYC Quarterly Reports
10-Q Quarterly Report November 2023
10-Q Quarterly Report August 2023
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report April 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report November 2023
10-Q Quarterly Report August 2023
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report April 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
GLYC Corporate News
Earnings Release
Financial Exhibit November 2023
Earnings Release
Financial Exhibit August 2023
Vote of Security Holders May 2023
Financial Exhibit
New Agreement April 2023
Earnings Release
Financial Exhibit March 2023
Regulated Disclosure March 2023
Financial Exhibit
Regulated Disclosure March 2023
Event for Officers February 2023
Earnings Release
Financial Exhibit November 2022
Financial Exhibit
Regulated Disclosure October 2022
Earnings Release
Financial Exhibit
Financial Exhibit
November 2023
Earnings Release
Financial Exhibit
Financial Exhibit
August 2023
Vote of Security Holders
May 2023
Financial Exhibit
New Agreement
New Agreement
April 2023
Earnings Release
Financial Exhibit
Financial Exhibit
March 2023
Regulated Disclosure
March 2023
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
March 2023
Event for Officers
February 2023
Earnings Release
Financial Exhibit
Financial Exhibit
November 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
October 2022
Last10K.com | 10-K Annual Report Fri Feb 28 2020
Document and Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2019 | Feb. 26, 2020 | Jun. 28, 2019 | |
| Document and Entity Information | |||
| Document Type | 10-K | ||
| Document Period End Date | Dec. 31, 2019 | ||
| Entity Registrant Name | GLYCOMIMETICS INC | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 399.5 | ||
| Entity Common Stock, Shares Outstanding | 43,582,979 | ||
| Document Fiscal Year Focus | 2019 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Central Index Key | 0001253689 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Amendment Flag | false |
View differences made from one year to another to evaluate Glycomimetics Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Glycomimetics Inc.
Assess how Glycomimetics Inc's management team is paid from their Annual Proxy
Glycomimetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Revenue - Product Highlight
We received an upfront cash payment of $9.0 million and, subject to the terms of the agreement, will be eligible to receive potential milestone payments totaling approximately $180.0 million, as well as tiered royalties ranging from the high single digits to 15%, as a percentage of net sales.
-
Financial - Expense Highlight
In assessing cash used in operating activities, we consider several principal factors: (i) net loss for the period; (ii) adjustments for non-cash charges including stock-based compensation expense and depreciation and amortization of property and equipment; and (iii) the extent to which receivables, accounts payable and other liabilities, or other working capital components increase or decrease.
-
Financial - Expense Highlight
Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.
-
Other - Other Highlight
At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and identify, as a performance obligation, and assess whether each promised good or service is distinct.
-
Financial - Expense Highlight
Clinical development expenses increased by $6.4 million, primarily as a result of increased clinical costs related to our ongoing global Phase 3 clinical trial of uproleselan in individuals with relapsed/refractory AML and the Phase 2/3 clinical trial being conducted by the NCI, which opened for enrollment in early 2019.
-
Revenue - Product
In March 2016, we entered...Read more
-
Financial - Expense
Research and development costs consist...Read more
-
Financial - Expense
The following table sets forth...Read more
-
Legal - Other
Legal expenses increased due to...Read more
-
Financial - Earnings
We cannot assure you that...Read more
-
Financial - Income
Interest income increased by $266,000...Read more
-
Revenue - Product
To date, we have financed...Read more
-
Revenue - Product
As of December 31, 2019,...Read more
-
Revenue - Product
To determine revenue recognition for...Read more
-
Financial - Dividend
Expected Dividend Yield?We have assumed...Read more
-
Financial - Expense
Personnel-related and stock-based compensation expenses...Read more
-
Other - Other
The foregoing table does not...Read more
-
Financial - Expense
Personnel-related and stock-based compensation expenses...Read more
-
Revenue - Product
Effective January 1, 2018, we...Read more
-
Other - Other
Following the effective date of...Read more
-
Other - Other
On February 5, 2020, Pfizer...Read more
-
Revenue - Product
Royalties: For arrangements that include...Read more
-
Financial - Expense
These third-party agreements are generally...Read more
-
Revenue - Product
In September 2017, we entered...Read more
-
Revenue - Geography
In May 2017, the European...Read more
-
Revenue - Product
The transaction price is then...Read more
-
Other - Other
If we raise additional funds...Read more
-
Financial - Expense
The capitalized amounts are expensed...Read more
-
Financial - Expense
We expect our research and...Read more
-
Other - Other
We will determine which programs...Read more
-
Financial - Expense
Our primary uses of capital...Read more
-
Other - Other
Our initial research and development...Read more
-
Revenue - Geography
In December 2018, at the...Read more
-
Revenue - Product
Under Topic 606, an entity...Read more
-
Financial - Expense
Our historical clinical accrual estimates...Read more
-
Other - Other
While our significant accounting policies...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Operations And Comprehensive Loss
Statements Of Stockholders' Equity
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Summary Of Accrued Expenses (Details)
Description Of The Business
Description Of The Business (Details)
Employee Benefit Plan
Employee Benefit Plan (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Nols And Carryforwards (Detail)
Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate And Effective Income Tax Rate (Detail)
Income Taxes - Schedule Of Gross Deferred Tax Asset And Related Valuation Allowance (Detail)
Income Taxes - Tax Cuts And Jobs Act (Details)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Details)
Net Loss Per Share Of Common Stock (Tables)
Operating Leases
Operating Leases (Details)
Operating Leases (Tables)
Operating Leases - Components Of Lease Expense (Details)
Operating Leases - Maturities Of Lease Liability (Details)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Tables)
Prepaid Expenses And Other Current Assets - Summary Of Prepaid Expenses And Other Current Assets (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited) (Detail)
Quarterly Financial Information (Unaudited) (Tables)
Research And License Agreements
Research And License Agreements - Additional Information (Details)
Stockholders Equity (Tables)
Stockholders' Equity
Stockholders' Equity - Common Stock Warrants (Details)
Stockholders' Equity - Company's Stock Option Activity (Details)
Stockholders' Equity - Equity Offerings (Details)
Stockholders' Equity - Incentive Plans (Details)
Stockholders' Equity - Stock-Based Compensation Expense (Details)
Stockholders' Equity - Summary Of Rsu Activity (Details)
Stockholders' Equity - Weighted-Average Assumptions (Details)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Property And Equipment (Detail)
Summary Of Significant Accounting Policies - Recently Issued Accounting Standards (Details)
Material Contracts, Statements, Certifications & more
Glycomimetics Inc provided additional information to their SEC Filing as exhibits
Exhibit 4.2: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 10.20: Material Contract
Exhibit 10.21: Material Contract
Exhibit 10.22: Material Contract
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: GLYC
CIK: 1253689
Form Type: 10-K Annual Report
Accession Number: 0001558370-20-001723
Submitted to the SEC: Fri Feb 28 2020 8:31:37 AM EST
Accepted by the SEC: Fri Feb 28 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/glyc/0001558370-20-001723.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...